ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5594-5601

  Johnatty, Sharon E ^a   Beesley, Jonathan ^a   Paul, Jim ^b   Fereday, Sian ^c   Spurdle, Amanda B ^a   M webb, Penelope ^a   Byth, Karen ^d   Marsh, Sharon ^h   McLeod, Howard ⁱ   Harnett, Paul R ^e,f   Brown, Robert ^j   Defazio, Anna ^e,g   Chenevix Trench, Georgia ^a,k  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Department of Medical Oncology and Palliative Care ^*  (Australia)

^g WESTMEAD HOSPITAL   (Australia)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ University of North Carolina   (United States)

^j HAMMERSMITH HOSPITAL   (United Kingdom)

^k ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DOCETAXEL; GLYCOPROTEIN P; TAXOID;

ADULT; AGED; ALLELE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OVARY TUMOR; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; TAXOIDS;

EID: 53049085702     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0606     Document Type: Article

References (40)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550-9.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.J Clin Oncol 2003;21:3194-200.
4. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-9.
5. Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 2005;17:399-411.
6. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006;107:1399-410.
7. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
8. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
9. Ueda K, Cornwell MM, Gottesman MM, et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986;141:956-62.
10. Sakaeda T, Nakamura T, Okumura K. Pharma-cogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003;4:397-410.
11. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996;6:610-7.
12. Kartner N, Shales M, Riordan JR, LingV. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 1983;43:4413-9.
13. Baekelandt MM, Holm R, Nesland JM,Trope CG, Kristensen GB. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 2000;20:1061-7.
14. Kioka N,Tsubota J, Kakehi Y, et al. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun 1989;162:224-31.
15. Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004;21:904-13.
16. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006;12:854-9.
17. Marsh S, King CR, McLeod HL, Paul J, Gifford G, Brown R. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin Cancer Res 2006;12:4127; author reply-9.
18. Marsh S, Paul J, King CR, Gifford G, Mc Leod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007;25:4528-35.
19. Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2007;122:170-6.
20. Vergote I, Rustin GJ, Eisenhauer EA, et al.; Gynecologic Cancer Intergroup. Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. J Natl Cancer Inst 2000;92:1534-5.
21. Ma LD, Marquardt D,Takemoto L, Center MS. Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. J Biol Chem 1991;266:5593-9.
22. ChambersTC, Pohl J, Raynor R L, Kuo JF. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem 1993;268:4592-5.
23. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43.
24. IllmerT, Schuler US,Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62:4955-62.
25. Meissner K, Jedlitschky G, Meyer zu Schwabedissen H, et al. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 2004;14:381-5.
26. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 2002;62:1-6.
27. Siegmund W, Ludwig K, Giessmann T, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002;72:572-83.
28. Morita N,Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 2003;65:1843-52.
29. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302.
30. de Jonge ME, van den Bongard HJ, Huitema AD, et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 2004;10:2237-44.
31. Wong M, Evans S, Rivory LP, et al. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther 2005;77:33-42.
32. Gurney H, Wong M, Balleine RL, et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 2007;82:33-40.
33. HoffmeyerS, BurkO, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8.
34. Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003;58:809-12.
35. Becquemont L, Verstuyft C, Kerb R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001;70:311-6.
36. Gerloff T,Schaefer M, Johne A, et al.MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002;54:610-6.
37. Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001;18:1400-4.
38. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005;15:693-704.
39. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525-8.
40. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003;13:481-94.